Arcellx Inc (ACLX) - Net Assets
Based on the latest financial reports, Arcellx Inc (ACLX) has net assets worth $402.35 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($603.99 Million) and total liabilities ($201.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Arcellx Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $402.35 Million |
| % of Total Assets | 66.62% |
| Annual Growth Rate | 61.57% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 192.15 |
Arcellx Inc - Net Assets Trend (2018–2025)
This chart illustrates how Arcellx Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Arcellx Inc for the complete picture of this company's asset base.
Annual Net Assets for Arcellx Inc (2018–2025)
The table below shows the annual net assets of Arcellx Inc from 2018 to 2025. For live valuation and market cap data, see Arcellx Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $402.35 Million | -11.53% |
| 2024-12-31 | $454.79 Million | -6.30% |
| 2023-12-31 | $485.38 Million | +136.82% |
| 2022-12-31 | $204.95 Million | +268.67% |
| 2021-12-31 | $-121.52 Million | -340.43% |
| 2020-12-31 | $50.54 Million | +254.38% |
| 2019-12-31 | $-32.74 Million | -333.91% |
| 2018-12-31 | $14.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arcellx Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 71068700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $56.00K | 0.01% |
| Other Comprehensive Income | $843.00K | 0.21% |
| Other Components | $1.13 Billion | 280.16% |
| Total Equity | $402.35 Million | 100.00% |
Arcellx Inc Competitors by Market Cap
The table below lists competitors of Arcellx Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gaztransport & Technigaz SAS
PA:GTT
|
$6.74 Billion |
|
GDS Holdings Limited
F:G40
|
$6.75 Billion |
|
NINGBO SHANSHAN GDR/A
F:OJ8
|
$6.75 Billion |
|
NEXGEN ENERGY LTD CDI/1
F:6NEA
|
$6.75 Billion |
|
JBTMarel Corp
NYSE:JBTM
|
$6.73 Billion |
|
Far East Smarter Energy Co Ltd
SHG:600869
|
$6.72 Billion |
|
Morningstar Inc
NASDAQ:MORN
|
$6.72 Billion |
|
MSA Safety
NYSE:MSA
|
$6.72 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arcellx Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 454,792,000 to 402,351,000, a change of -52,441,000 (-11.5%).
- Net loss of 228,934,000 reduced equity.
- Share repurchases of 1,303,000 reduced equity.
- New share issuances of 131,562,000 increased equity.
- Other comprehensive income decreased equity by 5,000.
- Other factors increased equity by 46,239,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-228.93 Million | -56.9% |
| Share Repurchases | $1.30 Million | -0.32% |
| Share Issuances | $131.56 Million | +32.7% |
| Other Comprehensive Income | $-5.00K | -0.0% |
| Other Changes | $46.24 Million | +11.49% |
| Total Change | $- | -11.53% |
Book Value vs Market Value Analysis
This analysis compares Arcellx Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.10x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.36x to 16.10x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $84.30 | $115.07 | x |
| 2019-12-31 | $-0.94 | $115.07 | x |
| 2020-12-31 | $2.32 | $115.07 | x |
| 2021-12-31 | $-3.62 | $115.07 | x |
| 2022-12-31 | $4.65 | $115.07 | x |
| 2023-12-31 | $10.10 | $115.07 | x |
| 2024-12-31 | $8.49 | $115.07 | x |
| 2025-12-31 | $7.15 | $115.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arcellx Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -56.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1027.25%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.50x
- Recent ROE (-56.90%) is below the historical average (-38.77%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -59.52% | 0.00% | 0.00x | 1.13x | $-9.70 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.70 Million |
| 2020 | -63.50% | 0.00% | 0.00x | 1.14x | $-37.15 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-51.78 Million |
| 2022 | -92.06% | -1053.37% | 0.06x | 1.53x | $-209.17 Million |
| 2023 | -14.56% | -64.08% | 0.13x | 1.70x | $-119.23 Million |
| 2024 | -23.60% | -99.46% | 0.15x | 1.56x | $-152.83 Million |
| 2025 | -56.90% | -1027.25% | 0.04x | 1.50x | $-269.17 Million |
Industry Comparison
This section compares Arcellx Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $190,374,900
- Average return on equity (ROE) among peers: -53.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arcellx Inc (ACLX) | $402.35 Million | -59.52% | 0.50x | $6.73 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $91.45 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $312.29 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $174.79 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $823.18 Million |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $10.00K | -200.00% | 3.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $540.89 Million | -31.04% | 0.29x | $3.64 Billion |
About Arcellx Inc
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a prod… Read more